Project Grant HT9425261E024
Award Date 7/1/26
Completion Date 6/30/29
Dollars Obligated $1.2M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10029, USA
Similar Awards
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded Icahn School of Medicine at Mount Sinai a Project Grant totaling $633,750 under the Military Medical Research and Development program (CFDA 12.420) for the period August 1, 2025, through July 31, 2028. The award supports research investigating the interplay between sensory neurons and natural killer (NK) cells during breast cancer metastatic dormancy. This three-year project advances the DHA's mission to transform healthcare for...
- Federal Grant Award Summary Icahn School of Medicine at Mount Sinai received a $507,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) for the period September 1, 2025 through August 31, 2027. The award supports investigation of tumor-intrinsic epigenetic mechanisms that modulate antitumor immune responses in metastatic prostate cancer. This research aligns with the program's focus on advancing biomedical innovations to...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded Icahn School of Medicine at Mount Sinai a $633,750 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective August 1, 2025, through July 31, 2028. This award supports research investigating the interplay between sensory neurons and natural killer (NK) cells during breast cancer metastatic dormancy. The research aims to advance understanding of mechanisms that suppress breast...
- Federal Grant Award Summary Icahn School of Medicine at Mount Sinai (ISMMS) received a $505,270 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) awarded on September 30, 2025, with a completion date of September 29, 2027. The award supports research investigating the impact of reprogrammed PIK3R1-insulin-glucose metabolism pathway in lethal prostate cancer to develop therapeutic strategy. This research aligns with the...
- Federal Project Grant Award Summary Icahn School of Medicine at Mount Sinai received a $591,500 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period August 1, 2025 through July 31, 2027. The award supports research titled "Decoding the Tumor Microenvironment Remodeling of Cancer Vaccine Treatment in Pleural Mesothelioma," to be conducted at the institution's New York, NY location. This project...
- Federal Grant Award Summary Icahn School of Medicine at Mount Sinai received a $466,809 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), effective September 1, 2025 through August 31, 2028. The award supports research to identify recessive prostate cancer risk alleles using data from the Million Veterans Program. This research initiative leverages the extensive genetic and health information available through the Million...
- Federal Project Grant Award Summary Icahn School of Medicine at Mount Sinai received a $2.18M Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to investigate metabolites and metabolic pathways associated with Crohn disease risk. The award, dated June 1, 2025, supports a four-year research initiative extending through June 30, 2029, conducted at the institution's New York campus. This biomedical research project aligns...
- Federal Grant Award Summary Icahn School of Medicine at Mount Sinai received a $2,065,452 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2025, through June 30, 2028. The award supports research titled "An Epigenetic Innate Immune Memory Hypothesis for Gulf War Illness: Development of a Pathophysiologically Based Diagnostic Biomarker Signature," which includes a fourth specific aim under...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded Icahn School of Medicine at Mount Sinai a $1.23M Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2025 through June 30, 2028. The award supports biomarker development research focused on refining an individualized risk-adapted approach to bladder-sparing treatment for muscle-invasive bladder cancer. This research initiative aims to advance clinical decision-making and...
- Federal Project Grant Award Summary Icahn School of Medicine at Mount Sinai received a $3.3M Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "Leveraging Personalized Stem Cell Therapy to Overcome Airway Reconstruction." The four-year award, which commenced June 1, 2025 and concludes May 31, 2029, supports advanced biomedical research aimed at developing innovative therapeutic...